As a revolutionary treatment for age-related macular degeneration (AMD), Lucentis has been a game-changer in the world of ophthalmology. But who is the mastermind behind this revolutionary medication? In this article, we’ll explore the history of Lucentis and the company responsible for its development and manufacturing. From its conception to its release, uncover the story of how this miracle drug came to be and the power behind its success.
Lucentis is a drug used to treat wet age-related macular degeneration (AMD), a leading cause of vision loss in people over age 50. It is manufactured by Genentech, a biotechnology company owned by Roche. Lucentis belongs to a family of drugs called anti-vascular endothelial growth factor (anti-VEGF), which work by blocking the growth of abnormal blood vessels in the retina that can cause vision loss.
Who Makes Lucentis?
Lucentis is a prescription drug used for the treatment of wet age-related macular degeneration (AMD). It is a medication developed by Genentech, a biotechnology company owned by Roche, that works by inhibiting vascular endothelial growth factor (VEGF) in the eye.
Genentech
Genentech, a wholly owned subsidiary of Roche, is the original manufacturer of Lucentis. Founded in 1976, Genentech is a leader in the biotechnology industry and has developed many groundbreaking drugs. As part of Roche, Genentech has access to Roche’s extensive research and development resources, which have enabled it to remain at the forefront of the biotechnology industry.
Manufacturing Process
Lucentis is manufactured by Genentech in their South San Francisco facility. The manufacturing process begins with the extraction of the active pharmaceutical ingredient (API) from human cells. The API is then purified and the drug is formulated into a suspension. The suspension is then filled into glass vials and packaged for distribution.
Distribution
Once the drug is manufactured, it is distributed to wholesalers, pharmacies, and hospitals. The drug is also distributed to doctors’ offices and clinics, where it is administered as an injection into the eye. The drug is then taken up by the patient and has its intended effect on the eye.
Few Frequently Asked Questions
Who Makes Lucentis?
Answer: Lucentis (ranibizumab), is a prescription medicine used to treat wet age-related macular degeneration (AMD). It is manufactured and marketed by Genentech, a subsidiary of Roche.
What is the Active Ingredient in Lucentis?
Answer: The active ingredient in Lucentis is ranibizumab, a recombinant humanized monoclonal antibody fragment. It works by blocking a protein known as vascular endothelial growth factor (VEGF) to reduce abnormal blood vessel growth in the eye, thereby preventing vision loss associated with wet AMD.
How Does Lucentis Work?
Answer: Lucentis works by blocking a protein known as vascular endothelial growth factor (VEGF). This protein promotes the growth of abnormal blood vessels in the eye, which can lead to vision loss associated with wet AMD. By blocking VEGF, Lucentis helps reduce the growth of these abnormal blood vessels and helps to maintain or improve vision.
What is the Recommended Dose for Lucentis?
Answer: The recommended dose for Lucentis is 0.5 mg per eye, administered by intravitreal injection. The dose may be repeated every four weeks, or as recommended by your doctor.
What are the Side Effects of Lucentis?
Answer: Common side effects of Lucentis include eye pain and redness, elevated intraocular pressure, cataracts, and increased risk of infection. Other rare but serious side effects can include inflammation in the eye, increased risk of stroke, and retinal detachment.
How is Lucentis Administered?
Answer: Lucentis is administered by intravitreal injection, which means an injection directly into the eye. This is done in a doctor’s office and should be done by a healthcare professional. The injection should be given in a sterile environment and the eye should be prepared prior to the injection.
Lucentis is a medication that is used to treat eye diseases such as wet age-related macular degeneration (AMD) and diabetic macular edema (DME). The medication is manufactured by the pharmaceutical company Genentech, a subsidiary of the Roche Group. Genentech has decades of experience in biotechnology and has developed a number of innovative products for the treatment of serious diseases. With a proven track record and years of experience, Genentech is the only pharmaceutical company that can provide safe and effective Lucentis. Genentech’s commitment to quality, innovation, and patient care makes them the clear choice for the production of Lucentis.